World Pharma Today, August 24, 2020
Authors: Wahid Awad, PhD, Chief Business Officer, CILcare and Michael Naimark, Director of Business Development, CBSET, Inc.
As the COVID-19 pandemic continues to spread across the world, clinicians, academic institutions, private organizations, and governments are working tirelessly to find treatments to help patients and at-risk populations threatened by this novel disease. In the absence of approved therapies, investigators are looking towards drug products indicated for other conditions with the goal of repurposing them for COVID-19 indications. Repurposing approved compounds carries both opportunities and risks, including a high risk of ototoxicity based on existing data on the drug classes under consideration.
This article will help you learn how including ototoxic assessment in a preclinical safety package for COVID-19 therapies can de-risk regulatory review, preserve patient hearing, and improve market positioning.